About Imspex Diagnostics
Imspex Diagnostics is a company based in Abercynon (United Kingdom) founded in 2011. Imspex Diagnostics has raised $2.23 million across 3 funding rounds from investors including European Union, Development Bank of Wales and ACF Investors. The company has 5 employees. Imspex Diagnostics has completed 1 acquisition, including GAS Dortmund. Imspex Diagnostics offers products and services including BreathSpec®, BreathSpec® V2, FlavourSpec®, FluidSpec™, and IMS GC-IMS. Imspex Diagnostics operates in a competitive market with competitors including Impedimed, Rigaku, Speclipse, Anvajo and Spectra Analysis, among others.
- Headquarter Abercynon, United Kingdom
- Employees 5
- SectorsHealthcare
- Email••••••••
- Website imspex.com
- Social LinkedIn X
- Legal Name Imspex Diagnostics Limited
- Date of Incorporation 17 Feb, 2011
- Jurisdiction ABERCYNON, RCT
- Annual Revenue$93.59 K (USD)-27as on Dec 31, 2022
- Net Profit-$673.88 K (USD)-54as on Dec 31, 2022
- Total Equity Funding$2.23M (USD)
in 3 rounds
- Latest Funding Round$1.6M (USD), Grant
May 2017
- InvestorsEuropean Union
& 2 more
- Employee Count5
- Investments & Acquisitions
Products & Services of Imspex Diagnostics
Imspex Diagnostics offers a comprehensive portfolio of products and services, including BreathSpec®, BreathSpec® V2, FlavourSpec®, FluidSpec™, and IMS GC-IMS.
Non-invasive tool for breath analysis in disease detection.
Enhanced device for advanced breathomics and health monitoring.
System for flavor detection in food and beverage quality.
Analyzer for fluid composition in industrial applications.
Combined method for precise gas and particle analysis.
Compact system for on-site environmental and industrial testing.
Funding Insights of Imspex Diagnostics
Imspex Diagnostics has successfully raised a total of $2.23M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.6 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.23M
- Total Rounds 3
- Last Round Grant — $1.6M
- First Round $2.23M
(Oct 2014)
- Investors Count 3
All 3 funding rounds of Imspex Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $1.6M | Grant | – | – | |
| Jan 2017 | $1.54M | Grant | – | – | |
| Oct 2014 | $2.23M | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Imspex Diagnostics
Imspex Diagnostics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Development Bank of Wales and ACF Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on angel investments | – | acfinvestors.com | Sheffield, United Kingdom | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Sustainable business finance is provided for companies in Wales. | – | financewales.co.uk | Wrexham, United Kingdom |
Investor details for Imspex Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Imspex Diagnostics
6 people are tracked at Imspex Diagnostics (2 in leadership, 1 in board & advisors, 3 in team); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
John McKinley | CEO | Leadership |
Thomas Wortelmann | Managing Director | Leadership |
Santi Dominguez | Founder & Chairman | Board & advisors |
Amber Jacobs | PR, Social Media & Marketing Manager | Team |
Lisa Davies | Administration & Finance Manager | Team |
Sheri Murrell | Project Manager For Innovate UK Industrial Biocontamination Project | Team |
Complete people profiles for Imspex Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Imspex Diagnostics
Imspex Diagnostics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GAS Dortmund.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of analytical sensors and instruments for trace detection of volatile compounds in various industries | gas-dortmund.de | Dortmund, Germany | 1997 | Jan 2013 | •••• |
Complete acquisition details for Imspex Diagnostics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Imspex Diagnostics
4 dated milestones of Imspex Diagnostics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Imspex Diagnostics is founded.
- Acquisition Acquires GAS Dortmund.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Grant, of $1.6M.
Competitors of Imspex Diagnostics
Imspex Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impedimed, Rigaku, Speclipse, Anvajo and Spectra Analysis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| impedimed.com | 1999 | Carlsbad, United States | $3.44M | 76 | Technologies for non-invasive fluid status assessment and monitoring are developed. | |
| rigaku.com | 1951 | Tokyo, Japan | – | 293 | XRD, XRF, SAXS, Raman, metrology, and crystallography solutions are provided. | |
| speclipse.com | 2015 | Seongnam-si, South Korea | $10.55M | – | Molecular spectroscopy systems for early skin cancer detection are provided. | |
| anvajo.com | 2016 | Dresden, Germany | $17.32M | 66 | Point-of-care solutions for laboratory diagnostics are provided by Anvajo. | |
| spectra-analysis.com | 2004 | Boston, United States | $9.25M | 6 | Infrared spectroscopic instruments are provided for molecular analysis. | |
| ahurascientific.com | 2002 | Wilmington, United States | $17M | – | Optical systems are developed for identifying solid and liquid chemicals. | |
| lineardiagnostics.com | 2011 | Birmingham, United Kingdom | $4.08M | 4 | Molecular diagnostic tests for sexually transmitted infections are developed. | |
| trinean.com | 2006 | Gentbrugge, Belgium | $9.45M | – | UV/VIS spectrometry solutions for biomolecular analysis are provided. | |
| magritek.com | 2004 | Wellington, New Zealand | – | – | Provider of NMR and MRI solutions for industries and research laboratories |
Detailed competitors of Imspex Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Imspex Diagnostics
The website of Imspex Diagnostics (imspex.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 60% vs previous month
Websites whose visitors overlap most with Imspex Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
google.co.uk | google.co.uk | 100% | – | #355 | – |
Latest news on Imspex Diagnostics
Complete news archive for Imspex Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Imspex Diagnostics
10 companies that operate in the same segment as Imspex Diagnostics (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Imspex Diagnostics
Imspex Diagnostics was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Imspex Diagnostics is headquartered in Abercynon, United Kingdom.
Imspex Diagnostics is a funded company, having raised a total of $2.23M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.23M, raised on Oct 2014.
Imspex Diagnostics has 5 employees.
Annual revenue of Imspex Diagnostics is $93.59K as on Dec 31, 2022.
Imspex is an analytical device manufacturer specialized in ion mobility spectroscopy and gas chromatography based instrumentation for diagnostics and industrial analytical applications. The company was formed as a spin-off of the University fo Glamorgan in 2011. Imspexs product line includes FlavourSpec - a GC instrument for the analysis of headspace of liquid and solid samples, primarily targeted for food and beverages, but can also find application in the analysis of volatiles from clinical samples like blood, urine etc., BreathSpec is designed for analysis of volatile organic compounds in human breath, GC-IMS-ODOR for on-site monitoring of methyl acrylate, ethyl acrylate and THT concentrations in natural gas, GC-IMS-SILOX for on-site reporting of siloxane in biogas.
Imspex Diagnostics's top competitors include Impedimed, Linear Diagnostics and Anvajo.
Imspex Diagnostics offers BreathSpec®, BreathSpec® V2, FlavourSpec®, FluidSpec™, and 2 more products and services.
Imspex Diagnostics has made 1 acquisition, including GAS Dortmund.
Imspex Diagnostics has 3 investors. Key investors include European Union, Development Bank of Wales, and ACF Investors.
Imspex Diagnostics operates through Imspex Diagnostics Limited.